Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 338)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 0
Gesamt: 389.994
Gesamt: 389.994
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BHC
7,0300
USD
-5,13 %
-0,3800 USD
Letzter Kurs 02:04:00 NYSE
Neuigkeiten
02.05.24 · Accesswire  |
25.04.24 · wO Chartvergleich |
11.04.24 · Accesswire |
11.04.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,230 | +447,06 | |
| 0,5700 | +55,23 | |
| 0,7200 | +47,03 | |
| 5,4500 | +41,56 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 0,9923 | -16,61 | |
| 5,2500 | -19,23 | |
| 0,7500 | -48,28 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 54.600.810 von X-Remi am 23.03.17 20:24:15
Also nichts wie raus X-Remi !!!!!!
Und in den Saftladen investierst Du dein Geld
Und so viel Zeit?Also nichts wie raus X-Remi !!!!!!
Valeant also said it needed to provide Papa with a "market competitive pay package" to "attract a proven, long-tenured sitting CEO." Of the $63 million Valeant compensation package, $8 million was meant to compensate Papa for the loss of stock awards he forfeited when he left Perrigo.
Meanwhile, leading executives at major companies that struggled far less than Valeant last year took pay cuts.
For instance, Apple cut CEO Tim Cook's 2016 pay by 15% because the iPhone maker suffered its first annual sales decline in 15 years. Yet Cook still led Apple to an incredible $46 billion in profits last year.
Likewise, last week Goldman Sachs announced CEO Lloyd Blankfein took a 4% pay cut last year due to slumping revenue and a revamped compensation structure.
Meanwhile, leading executives at major companies that struggled far less than Valeant last year took pay cuts.
For instance, Apple cut CEO Tim Cook's 2016 pay by 15% because the iPhone maker suffered its first annual sales decline in 15 years. Yet Cook still led Apple to an incredible $46 billion in profits last year.
Likewise, last week Goldman Sachs announced CEO Lloyd Blankfein took a 4% pay cut last year due to slumping revenue and a revamped compensation structure.
was für ein saftladen...jeder bedient sich an der Kasse....63 Million$ für 8 Monate verdient Papa...toll...dann hat die Firma nur noch 450million in der Kasse...dann kommen noch Gehälter der Aufsichtsrete und ist null in der Kasse...tollllllllllllllll
bin heute auch mal wieder an Board gegangen 
Gutes Gelingen
Gutes Gelingen
http://www.conferencecalltranscripts.org/no/summary2/?id=361…
On behalf of the Board of Directors of Valeant Pharmaceuticals International, Inc. (the Company), I want to take this opportunity to invite you to attend our 2017 Annual Meeting of Shareholders. The meeting will be held at 9:00 a.m., local time, on Tuesday, May 2, 2017 at the Companys offices located at 2150 Saint Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8. At the meeting, shareholders will vote on the proposals set forth in the Notice of Annual Meeting and the accompanying management proxy circular and proxy statement (the Proxy Statement), as well as receive a report on the progress of the Company.
On behalf of the Board of Directors of Valeant Pharmaceuticals International, Inc. (the Company), I want to take this opportunity to invite you to attend our 2017 Annual Meeting of Shareholders. The meeting will be held at 9:00 a.m., local time, on Tuesday, May 2, 2017 at the Companys offices located at 2150 Saint Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8. At the meeting, shareholders will vote on the proposals set forth in the Notice of Annual Meeting and the accompanying management proxy circular and proxy statement (the Proxy Statement), as well as receive a report on the progress of the Company.
Trading Spotlight
Why It May Not Be A Good Idea To Short Valeant Stock Right Now
http://amigobulls.com/articles/why-it-may-not-be-a-good-idea…
eindeutig wieder mal Leerverkäufe...immer bei positiven Nachrichten reagieren die Shroti mit Leerverkäufe darauf....
ich habe mir den Chartverlauf seit Sep. 2016 angeschaut...Aktie von über 30$ auf jetztiger Kurs..was ist passiert.. Schilden waren im Sept. auch schon bekannt.... Aussichten und Prognose war auch so erwartet....
im Gegenteil sind 1 Monat viel positive Meldungen gekommen und neue Zulassungen, Refinanzierung, Schuldenabbau, Schuldenfälligkeit verschoben...
das wird sich irgendwann in den Kurs niederschlagen müssen und werden und ist die Rache richtig süß
ich habe mir den Chartverlauf seit Sep. 2016 angeschaut...Aktie von über 30$ auf jetztiger Kurs..was ist passiert.. Schilden waren im Sept. auch schon bekannt.... Aussichten und Prognose war auch so erwartet....
im Gegenteil sind 1 Monat viel positive Meldungen gekommen und neue Zulassungen, Refinanzierung, Schuldenabbau, Schuldenfälligkeit verschoben...
das wird sich irgendwann in den Kurs niederschlagen müssen und werden und ist die Rache richtig süß
Bausch + Lomb Canada Launches BEPREVE®
Latest Eye Health Innovation Indicated for Seasonal and Chronic Eye Allergies to "Stop the Itch"LAVAL, QC, March 22, 2017 /CNW/ - Bausch + Lomb, a leading global eye health company, today announced through its Canadian affiliate the availability in Canada of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%w/v, an innovative fast acting eye drop indicated for the treatment of itch associated with allergic conjunctivitis.
Allergic conjunctivitis is inflammation of the eye caused by an allergic reaction to allergens such as pollen, house dust, or animal dander. Affecting as many as 30% of the population, allergic conjunctivitis is increasing in incidence.1
"In my practice, I see many patients who suffer from allergic conjunctivitis and experience discomfort from itchy eyes," said Randall Thomas, M.D., an ophthalmologist from Concord, North Carolina. "BEPREVE® has been a welcome medicine that has allowed me to effectively help patients with itchy eyes due to seasonal and chronic allergies."
BEPREVE® is the first innovative product for allergic conjunctivitis to be introduced to the Canadian market in six years. It is a dual acting antihistamine that works by blocking the effects of histamine - a chemical that plays an important role in allergic reactions, and stabilizing mast cells - cells that contain chemicals involved in allergic reactions. In clinical trials, BEPREVE® demonstrated a 73.4% reduction in itchy eyes in as rapidly as three minutes.2
"Bausch + Lomb Canada is proud to offer patients an innovative product that reduces the intensity of allergic reactions and associated eye itchiness, allowing them to focus on what is important in their lives," says Lorenzo Santini, general manager, Bausch + Lomb Canada. "BEPREVE® will complement Bausch + Lomb's existing prescription ophthalmology family of products, including ALREX®, LOTEMAX® Gel, PROLENSA®, and branded OTC eye vitamins, PreserVision® and Ocuvite®."
Valeant Completes Refinancing Transactions
http://ih.advfn.com/p.php?pid=nmona&article=74149223Valeant Completes Refinancing Transactions
http://ih.advfn.com/p.php?pid=nmona&article=74149226
Current Report Filing (8-k)
http://ih.advfn.com/p.php?pid=nmona&article=74149488
Durchsuchen
25.04.24 · wO Chartvergleich · BAVARIA Industries Group Akt |
04.03.24 · wO Chartvergleich · Myriad Genetics |